Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

1 in 6 cases of EVALI can be traced back to legal THC vapes

Data released by the Centers for Disease Control and Prevention on Jan. 14 revealed that one in six cases of vaping-related lung illness, or EVALI, can be linked to legally purchased cannabis products.

Thumbnail

Women’s blood vessels age quicker than men’s

Women’s blood vessels age at a faster rate than men’s, researchers from the Smidt Heart Institute at Cedars-Sinai reported this month—a finding that could explain some of the considerable sex gaps in CVD in men and women.

Thumbnail

Study proves diabetes is an independent predictor of HF

A cross-structural analysis published in Mayo Clinic Proceedings this January independently links diabetes to the development of heart failure, suggesting diabetic cardiomyopathy is a real—and growing—issue in the U.S.

Thumbnail

Keto diet is too high-fat for heart patients, cardiologist warns

One Minneapolis cardiologist is concerned that people following the trendy Keto diet aren’t worrying enough about their fat intake.

Thumbnail

How engineering could optimize the artificial heart valve

Redesigning the artificial heart valve could improve blood flow and potentially eliminate the need for blood thinners in patients with mechanical support, according to a new study.

Thumbnail

Amarin tailors educational campaign to people at persistent CV risk

Amarin on Jan. 13 announced the launch of True to Your Heart, a new educational campaign geared toward heart patients who remain at a persistent risk for CVD despite being treated with statins and other standard-of-care therapies.

Thumbnail

NHS, Novartis partner to save 30K lives with new CV drug

Pharmaceutical company Novartis has partnered with the U.K.’s National Health Service to study inclisiran, an investigational cholesterol-lowering drug that experts project could save 30,000 lives over the next decade.

Thumbnail

FDA reports more ranitidine recalls

The FDA has added at least three additional items to its growing roster of heartburn drug recalls.